Prostate cancer (PCa) is a major health concern worldwide ([@bibr5-1557988319854555]). In Belgium, nearly 8,000 new cases are diagnosed each year ([@bibr3-1557988319854555].), of which 89% present with stage I--III disease and these patients may be considered candidates for radical local treatment ([@bibr3-1557988319854555].). Robot-assisted laparoscopic prostatectomy (RALP) is becoming the new standard of treatment in the local control of disease, with comparable oncologic outcomes to the open approach ([@bibr18-1557988319854555]). After cancer control, the surgeon's main focus while performing radical prostatectomy is the preservation of urinary continence and, where indicated, of sexual potency. Great effort has been made by the urological community in order to maximize these two functional outcomes. The robotic platform, by increasing dexterity, reducing surgical trauma, magnifying vision, and allowing better preservation of anatomical structures, has indeed determined a shift in radical prostatectomy functional recovery ([@bibr19-1557988319854555]; [@bibr23-1557988319854555]), although controversy remains whether such an advantage is true in the long term and when comparing with highly skilled open surgeons ([@bibr20-1557988319854555]; [@bibr29-1557988319854555]). Clearly, an element of major bias in most studies exploring erectile function and continence after prostatectomy is the variability in the definitions of "continence" and "potency" ([@bibr4-1557988319854555]). Deciding whether surgery was *functionally successful* only by weighing a urinary pad or asking a patient if his erections are adequate is clearly reductive and a poor proxy of good surgery. For example, not wearing a protection pad does not at all exclude a urinary leakage ([@bibr16-1557988319854555]). A wider analysis of quality of life (QoL) outcomes, tailored to the individual patient and evaluating the overall impact of radical prostatectomy and PCa, is needed and should be implemented when exploring continence and erectile function results, since each individual may experience and suffer incontinence and impotence in a different manner as these are continuous and not categoric phenomena.

The European Organization for Research and Treatment of Cancer (EORTC) has introduced validated questionnaires to explore QoL in oncologic patients ([@bibr25-1557988319854555]). These include the EORTC Quality of Life Questionnaire C30 (QLQ-C30; [@bibr1-1557988319854555]), which is the core questionnaire for all cancer patients to evaluate QoL in clinical trials, and the EORTC PR25, specifically designed for men harboring PCa. Although studies exist analyzing QoL modifications after radical prostatectomy ([@bibr6-1557988319854555]; [@bibr27-1557988319854555]), these are scarce and the majority of data is extrapolated from open cohorts ([@bibr6-1557988319854555]).

The aim of the current study is to analyze functional outcomes and QoL scores after RALP in a prospective series of two Belgian centers (Hopital Erasme and Institut Jules Bordet), evaluating their modifications and exploring potential risk factors for QoL degradation after surgery.

Materials and Methods {#section1-1557988319854555}
=====================

After institutional review board approval and ethics committee approval (Be-RALP study, Registre du Cancer Belge, RIZIV/INAMI), beginning in January 2010 until December 2015, all patients undergoing RALP with or without pelvic node dissection in two academic centers in Belgium (Hopital Erasme and Institut Jules Bordet) were prospectively enrolled in the Belgian Cancer Registry, Be-RALP study. Patients signed written informed consent to participate in the study. All patients harbored clinically localized or locally advanced PCa. Exclusion criteria were all men who underwent salvage RALP after failure of any kind of primary treatment for PCa (brachytherapy, radiotherapy, high-intensity focused ultrasound \[HIFU\]) as well as all patients who had received any form of hormonal treatment for PCa in the 12 months prior to surgery. Patients undergoing cytoreductive prostatectomy for metastatic PCa were excluded.

Questionnaires {#section2-1557988319854555}
--------------

Patients were invited to anonymously fill four questionnaires prior to surgery: the 5-item version of the International Index of Erectile Function (IIEF-5), the International Consultation on Incontinence Questionnaire Short Form (ICIQ-SF), the EORTC PR25, and the EORTC QLQ-C30. After surgical planning, the patients received the questionnaires and were asked to answer the questions at home. Questionnaires were then retrieved by a specialized nurse and blindly inserted in the Belgian Cancer Registry via an Internet access program.

The ICIQ-UI Short Form provides a brief and robust measure to assess the impact of the symptoms of incontinence on QoL and outcome of treatment. This short and simple questionnaire is also of use to urologists to obtain a brief yet comprehensive summary of the level, impact, and perceived cause of symptoms of incontinence and to facilitate patient--clinician discussions. Its brevity also makes the ICIQ-UI Short Form an ideal research tool. The questionnaire is scored from 0 to 21, with 0 being the absolute absence of incontinence and 21 being major incontinence.

The IIEF-5 is a widely used, multidimensional questionnaire for the evaluation of male sexual function. It is recommended for the diagnostic evaluation of erectile dysfunction (ED) severity and as the end point for clinical trials. The IIEF-5 score is the sum of the ordinal responses to the five items and allows the categorization of erectile dysfunction. Scores 22--25 are associated with *No erectile dysfunction*; 17--21: *Mild erectile dysfunction*; 12--16: *Mild to moderate erectile dysfunction*; 8--11: *Moderate erectile dysfunction*; and 5--7: *Severe erectile dysfunction*.

Two separated, EORTC-validated questionnaires were given to patients. While the C30 is a questionnaire common to multiple cancers, the PR25 is specifically designed for PCa patients. The former is divided into 15 items: 6 are functional scales (global, physical, role functioning, emotional functioning, cognitive, and social QoL), for which a higher score means a higher QoL. The 9 items are symptom scales (financial, fatigue, nausea, pain, dyspnea, insomnia, appetite, constipation, and diarrhea), for which a higher score means a poorer QoL. The questionnaire PR25, specific for PCa, is composed of 25 questions and allows a quantification of urinary symptoms, bother related to incontinence aid, bowel symptoms, hormone treatment--related symptoms (hot flushes, gynecomastia, lower extremity edema, weight alterations, and feeling less masculine), sexual activity, and sexual functioning. All scores of EORTC QoL questionnaires are expressed in percentages (0%--100%), following EORTC recommendations ([@bibr7-1557988319854555]).

Surgery {#section3-1557988319854555}
-------

Surgery was performed via the robotic platform DaVinci S or SI, according to the hospital. Three experienced surgeons (\>200 RALP cases performed prior to study) performed all surgeries. All patients underwent a transperitoneal, anterograde radical prostatectomy. Pelvic node dissection was performed according to preoperative Briganti nomogram. Unilateral or bilateral nerve sparing was performed according to patient--surgeon preoperative discussion and if judged oncologically safe. Patients then responded to the four questionnaires at 1, 3, 12, and 24 months after RALP. Each questionnaire was responded to anonymously by the patient at home right before the follow-up consultation. Regarding adjuvant or salvage radiotherapy and hormone therapy, patients were treated according to clinical, pathologic, and biochemical characteristics and based on multidisciplinary team decision. Patients regularly underwent pelvic floor muscle training beginning at 4 weeks after surgery, until satisfactory continence control was achieved.

Statistical Analysis {#section4-1557988319854555}
--------------------

Descriptive statistics were used to depict variables across different postoperative phases. All scores of QoL questionnaires (PR25 and Q30) were expressed as percentages. Distributions of QoL scores on various time moments were compared to preoperative values using Wilcoxon signed-rank sum test. Univariate and multivariate linear regressions were performed to assess associations between potential risk factors and PR25 QoL outcomes (continuous, 0--100). Univariate and multivariate linear regression models were then constructed to assess risk factors for postoperative EORTC PR25 QoL scores, on early follow-up (3 months) and late follow-up (24 months). All statistical analyses were performed using Stata 13.1 (StataCorp, College Station, TX). Associations with *p* value ≤.05 were considered statistically significant.

Results {#section5-1557988319854555}
=======

Overall, 584 patients completed ICIQ-SF, IIEF5, and EORTC PR25 questionnaires and were included in the final analysis. Concerning the EORTC QLQ-C30, subanalysis was restricted to 345 patients having completed the questionnaire. [Table 1](#table1-1557988319854555){ref-type="table"} illustrates global patient characteristics. Of note, 60% (353/584) of the patients underwent bilateral nerve-sparing RALP, 18% (104/584) had unilateral nerve sparing, and 22% (127/584) did not receive a nerve-sparing procedure.

###### 

General Characteristics of the Cohort.

![](10.1177_1557988319854555-table1)

  -------------------------------------------------
  Age (years)                    64 (59--68)\
                                 64 ± 7
  ------------------------------ ------------------
  PSA (ng/ml)                    7.1 (4.8--10.2)\
                                 9.6 ± 10.9

  Family history of PCa          

   No                            385 (66%)

   Yes                           38 (7%)

   Unknown                       161 (27%)

  cT                             

   ≤1c                           320 (55%)

   2a--c                         224 (38%)

   ≥3a                           40 (7%)

  Pathologic Gleason score       

   6 (3 + 3)                     265 (45%)

   7 (3 + 4)                     179 (31%)

   7 (4 + 3)                     82 (14%)

   8                             33 (6%)

   9--10                         25 (4%)

  pT                             

   2a                            33 (6%)

   2b                            36 (6%)

   2c                            316 (54%)

   3a                            138 (24%)

   3b                            60 (10%)

   4                             1 (0.2%)

  pN                             

   0                             220 (38%)

   1                             29 (5%)

   X                             335 (57%)

  Surgical margins               

   Negative                      440 (75%)

   Positive                      144 (25%)

  Nerve sparing                  

   None                          127 (22%)

   Unilateral                    104 (18%)

   Bilateral                     353 (60%)

   EBL (ml)                      250 (150--400)\
                                 326 ± 294

  Radiotherapy                   

   None                          545 (93%)

   \<3 months                    3 (0.5%)

   \<12 months                   27 (5%)

   \<24 months                   9 (1.5%)

  Androgen deprivation therapy   

   None                          568 (97%)

   3 months                      10

   12 months                     15

   24 months                     16
  -------------------------------------------------

*Note*. EBL = estimated blood loss; PCa = prostate cancer; PSA = prostate-specific antigen.

International Consultation on Incontinence Questionnaire Short Form {#section6-1557988319854555}
-------------------------------------------------------------------

Regarding preoperative continence status ([Table 2](#table2-1557988319854555){ref-type="table"}), mean ICIQ was 1.9, though it must be underlined that ICIQ was equal to 0 (no leakage at all) in 77% of patients; a nonnegligible number of patients thus presented already urinary leakage in the preoperative setting, with 8% of the cohort having an ICIQ 1--5, 10% an ICIQ score of 6--10, and 5% having an ICIQ of 11--21 (indicating significant leakage). In the immediate postoperative period, a significant (*p* \< .001) increase in ICIQ scores was observed, rising to a mean of 10 ± 6 at 1 month after surgery and showing an overall decrease during follow-up to a mean value of 4, 1 and 2 years after RALP, yet significantly higher compared to preoperative values (*p* \< .001). Of note, 2 years after surgery 41% (240/584) of patients reported an ICIQ of 0, meaning no leakage whatsoever, 47% (274/584) had an ICIQ 1--10, and 12% (70/584) had a persistent ICIQ \>11.

###### 

ICIQ and IIEF Modifications Following RALP.
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  ----------------------------------------------------------------------------------------------------
  Preoperative                      *p* value^[a](#table-fn3-1557988319854555){ref-type="table-fn"}^
  ------------------- ------------- ------------------------------------------------------------------
   ICIQ               0 (0--0)\     ---
                      1.9 ± 5       

   IIEF               16 (5--22)\   
                      14 ± 10       

  1 month post-op                   

   ICIQ               9 (6--14)\    \<.001
                      10 ± 6        

   IIEF               1 (1--4)\     \<.001
                      3 ± 4         

  3 months post-op                  

   ICIQ               7 (2--11)\    \<.001
                      7 ± 6         

   IIEF               2 (1--6)\     \<.001
                      5 ± 5         

  12 months post-op                 

   ICIQ               4 (0--7)\     \<.001
                      4 ± 5         

   IIEF               4 (1--13)\    \<.001
                      7 ± 7         

  24 months post-op                 

   ICIQ               3 (0--7)\     \<.001
                      4 ± 5         

   IIEF               5 (1--16)\    \<.001
                      8 ± 8         
  ----------------------------------------------------------------------------------------------------

*Note*. ICIQ = International Consultation on Incontinence Questionnaire; IIEF = International Index of Erectile Function.

Wilcoxon signed rank sum test compared to pre-op value.

Five-Item Version of the International Index of Erectile Function {#section7-1557988319854555}
-----------------------------------------------------------------

At baseline, median IIEF-5 was 16 (5--22), with only 28% (164/584) of patients showing no signs of ED (IIEF-5 ≥22) and 31% (181/584) of the cohort presenting with severe baseline ED ([Table 2](#table2-1557988319854555){ref-type="table"}). IIEF scores at 1 and 3 months after surgery show a major decline in erectile function, with 82%--88% of men unable to obtain rigid erections. On future follow-up, we observed an amelioration of erectile function. These data must be interpreted with caution as they represent the erectile function of the entire cohort, including men with baseline ED and those in whom a non-nerve-sparing procedure was performed; if considering only patients with a preoperative IIEF5 \>11 and nerve-sparing procedures, 56% (81/145) of these men had an IIEF \>11 at 2-year follow-up after RALP.

QoL According to EORTC PR25 {#section8-1557988319854555}
---------------------------

[Figure 1](#fig1-1557988319854555){ref-type="fig"} illustrates the modifications of QoL according to the PR25 questionnaire. Globally, all items were significantly deteriorated (*p* ≤ .04) 1 month after surgery on first follow-up, with the greatest difference seen in sexual function (Δ 45%). "Bowel symptoms" were the first item to return to nonsignificantly different values compared to the preoperative status, returning to baseline at 3 months after surgery. For urinary symptoms instead, 12 months were necessary to restore preoperative scores, which at 24 months were even better compared to preoperative values, though this difference appeared nonsignificant (16 vs. 13, *p* = .15). On the other hand, patients who continued to present urinary incontinence referred a deteriorated QoL score concerning "bother from incontinence aid," even 2 years after surgery. Both sexual activity and sexual function items were significantly decreased after surgery. However, sexual activity (which does not necessarily require intercourse) exhibited a steady recovery, returning to values not significantly different from baseline at 24 months (*p* = .65). Sexual function, which analyzes erections, ejaculation, feeling comfortable about sex, and enjoying sex, was dramatically reduced by RALP. Although scores did ameliorate with ongoing follow-up, the reported scores 2 years after surgery remained significantly inferior compared to preoperative sexual functioning (72% vs. 41%, *p* \< .001).

![Modifications of QoL scores after RALP according to the EORTCPR25 questionnaire. QoL = quality of life; RALP = robot-assisted laparoscopic prostatectomy; and EORTCPR25 = European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Prostate Cancer](10.1177_1557988319854555-fig1){#fig1-1557988319854555}

Risk Factors for QoL Modifications {#section9-1557988319854555}
----------------------------------

On univariate and multivariate linear regressions, multiple factors associated with postoperative deterioration of QoL scores were found ([Tables 3](#table3-1557988319854555){ref-type="table"} and [4](#table4-1557988319854555){ref-type="table"}). Concerning urinary symptoms, preoperative score was significantly and positively associated with 3- and 24-month scores (*p* \< .001). Bowel symptoms appeared to be positively associated both with preoperative scores (*p* \< .001) and non-specimen-confined disease (≥pT3b or pN1 or R1). Treatment-related symptoms showed significant association with preoperative scores and non-specimen-confined disease and the strongest association with hormone therapy. These associations remained significant 2 years after RALP. Analyzing sexual activity, on univariate linear regression, age, non-specimen-confined disease, and hormone therapy were inversely associated with such QoL score. Preoperative sexual activity score, preoperative IIEF5, and bilateral nerve sparing, all significantly predicted 3-month and 24-month sexual activity scores. On multivariate analysis only preoperative score (positive association) and early hormone therapy (inverse association) were significant predictors of sexual activity at 3 months, while at 2 years only age (inverse) and preoperative score were significantly associated. Similarly, regarding sexual functioning, multiple risk factors analyzed were significantly associated with 3- and 24-month scores, including age, preoperative sexual functioning, preoperative IIEF5, bilateral nerve sparing, non-specimen-confined disease, and early hormone therapy. Nonetheless, on multivariate analysis, only age (inverse) and preoperative score significantly predicted sexual functioning scores.

###### 

Univariate and Multivariate Analysis Exploring Association Between Risk Factors and QoL at 3 Months Post-Op.

![](10.1177_1557988319854555-table3)

                                                                                              Univariate                                         Multivariate             
  ------------------------------------------------------------------------------- ----------- ------------------------ ------------ ------------ ------------------------ ------------
  Urinary symptoms                                                                                                                                                        
   Age                                                                            0.07        \[--0.14, 0.29\]         .48          0.002        \[--0.21, 0.22\]         .99
   Pre-op urinary symptoms                                                        **0.35**    **\[0.26, 0.44\]**       **\<.001**   **0.35**     **\[0.26, 0.44\]**       **\<.001**
   Pre-op ICIQ                                                                    0.17        \[--0.88, 0.42\]         .20          −0.04        \[--0.29, 0.21\]         .73
   Non-specimen confined^[a](#table-fn5-1557988319854555){ref-type="table-fn"}^   1.37        \[--1.8, 4.6\]           .40          0.54         \[--2.58, 3.66\]         .73
   Nerve sparing unilateral                                                       −2.49       \[--7.2, 2.25\]          .30          −1.13        \[--5.69, 3.42\]         .62
   Nerve sparing bilateral                                                        −2.59       \[--6.3, 1.14\]          .17          −0.91        \[--4.61, 2.80\]         .63
  Incontinence aid                                                                                                                                                        
   Age                                                                            0.27        \[--0.11, 0.65\]         .16          0.39         \[--0.06, 0.84\]         .09
   Pre-op incontinence aid                                                        −0.029      \[--0.28, 0.23\]         .82          −0.10        \[--0.37, 0.17\]         .46
   Pre-op ICIQ                                                                    0.36        \[--0.14, 0.86\]         .16          0.63         \[--0.26, 1.53\]         .16
   Non-specimen confined^[a](#table-fn5-1557988319854555){ref-type="table-fn"}^   −2.6        \[--8.1, 2.97\]          .36          −1.64        \[--8.04, 4.76\]         .62
   Nerve sparing unilateral                                                       −1.32       \[--9.36, 6.72\]         .75          −0.49        \[--9.46, 8.47\]         .91
   Nerve sparing bilateral                                                        −1.12       \[--7.47, 5.22\]         .73          −0.57        \[--7.98, 6.84\]         .88
  Bowel symptoms                                                                                                                                                          
   Age                                                                            −0.004      \[--0.12, 0.11\]         .94          −0.01        \[--0.12, 0.10\]         .84
   Pre-op bowel                                                                   **0.19**    **\[0.10, 0.28\]**       **\<.001**   **0.19**     **\[0.10, 0.28\]**       **\<.001**
   Non-specimen confined^[a](#table-fn5-1557988319854555){ref-type="table-fn"}^   **1.88**    **\[0.28, 3.49\]**       **.02**      **1.75**     **\[0.16, 3.34\]**       **.03**
  Treatment-related symptoms                                                                                                                                              
   Age                                                                            −0.04       \[--0.18, 0.10\]         .54          −0.07        \[--0.19, 0.05\]         .26
   Pre-op treatment related                                                       **0.40**    **\[0.32, 0.47\]**       **\<.001**   **0.38**     **\[0.30, 0.45\]**       **\<.001**
   Non-specimen confined^[a](#table-fn5-1557988319854555){ref-type="table-fn"}^   **3.27**    **\[1.28, 5.25\]**       **\<.001**   **1.96**     **\[0.11, 3.81\]**       **.038**
   Early hormone therapy                                                          **13.03**   **\[5.49, 20.56\]**      **\<.001**   **7.9**      **\[0.85, 14.9\]**       **.028**
  Sexual activity                                                                                                                                                         
   Age                                                                            **−0.39**   **\[--0.75, --0.02\]**   **.04**      0.01         \[--0.36, 0.39\]         .96
   Pre-op sexual activity                                                         **0.32**    **\[0.24, 0.41\]**       **\<.001**   **0.29**     **\[0.19, 0.39\]**       **\<.001**
   Pre-op IIEF-5                                                                  **0.51**    **\[0.26, 0.76\]**       **\<.001**   0.08         \[--0.20, 0.37\]         .57
   Non-specimen confined^[a](#table-fn5-1557988319854555){ref-type="table-fn"}^   **−5.54**   **\[--10.9, --0.17\]**   **.04**      −2.4         \[--7.7, 2.9\]           .37
   Nerve sparing unilateral                                                       3.26        \[--4.7, --11.19\]       .42          −1.7         \[--9.5, 6.1\]           .67
   Nerve sparing bilateral                                                        **8.75**    **\[2.50, 15.00\]**      **.006**     1.9          \[--4.5, 8.3\]           .56
   Early hormone therapy                                                          **−29.8**   **\[--50.2, --9.43\]**   **.004**     **−22.97**   **\[--42.6, --2.5\]**    **.03**
  Sexual functioning                                                                                                                                                      
   Age                                                                            **−1.22**   **\[--1.56, --0.87\]**   **\<.001**   **−1.04**    **\[--1.44, --0.65\]**   **\<.001**
   Pre-op sexual functioning                                                      **0.17**    **\[0.08, 0.27\]**       **\<.001**   0.06         \[--0.05, 0.17\]         .32
   Pre-op IIEF-5                                                                  **0.77**    **\[0.48, 1.04\]**       **\<.001**   0.25         \[--0.14, 0.66\]         .21
   Non-specimen confined^[a](#table-fn5-1557988319854555){ref-type="table-fn"}^   −0.45       **\[--9.92, 0.83\]**     .09          −3.6         \[--9.17, 2.05\]         .21
   Nerve sparing unilateral                                                       6.08        \[--1.86, 14.01\]        .13          4.4          \[--3.80, 12.6\]         .29
   Nerve sparing bilateral                                                        **9.38**    **\[3.03, 15.7\]**       **.004**     3.6          \[--3.2, 10.5\]          .30
   Early hormone therapy                                                          −20.3       \[--46.02, 5.47\]        .12          −13.05       \[--38.2, 12.1\]         .31

*Note*. Coeff = coefficient; IIEF = 5-item version of the International Index of Erectile Function; ICIQ = International Consultation on Incontinence Questionnaire; QoL = quality of life.

Non-specimen-confined disease ≥pT3b or pN1 or R1.

###### 

Univariate and Multivariate Analysis Exploring Association Between Risk Factors and QoL at 24 Months Post-Op.
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                                                                                               Univariate                                        Multivariate             
  ------------------------------------------------------------------------------- ------------ ------------------------ ------------ ----------- ------------------------ ------------
  Urinary symptoms                                                                                                                                                        
   Age                                                                            0.03         \[--0.21, 0.26\]         .83          −0.02       \[--0.25, 0.21\]         .84
   Pre-op urinary symptoms                                                        **0.29**     **\[0.19, 0.38\]**       **\<.001**   **0.28**    **\[0.18, 0.38\]**       **\<.001**
   Pre-op ICIQ                                                                    0.08         \[--0.14, 0.30\]         .49          0.03        \[--0.18, 0.24\]         .78
   Non-specimen confined^[a](#table-fn7-1557988319854555){ref-type="table-fn"}^   1.66         \[--1.63, 4.94\]         .32          1.06        \[--2.2, 4.30\]          .51
   Nerve sparing unilateral                                                       −1.87        \[--6.83, 3.09\]         .46          −0.99       \[--5.77, 3.80\]         .68
   Nerve sparing bilateral                                                        −1.97        \[--5.96, 2.02\]         .33          −0.64       \[--4.61, 3.34\]         .75
   Early RT                                                                       **20.14**    **\[1.39, 38.9\]**       **.035**     **19.43**   **\[1.22, 37.6\]**       **.037**
   Any RT                                                                         1.72         \[--3.5, 6.98\]          .52          −0.08       \[--5.77, 5.61\]         .98
  Incontinence aid                                                                                                                                                        
   Age                                                                            0.066        \[--0.23, 0.36\]         .66          −0.22       \[--0.66, 0.22\]         .32
   Pre-op incontinence aid                                                        0.21         \[--0.23, 0.65\]         .35          0.20        \[--0.25, 0.65\]         .38
   Pre-op ICIQ                                                                    −0.08        \[0.36, 0.19\]           .55          −0.09       \[--0.53, 0.34\]         .68
   ^[a](#table-fn7-1557988319854555){ref-type="table-fn"}^Non-specimen confined   −1.85        \[--5.97, 2.28\]         .38          −3.9        \[--10.5, 2.74\]         .25
   Nerve sparing unilateral                                                       0.0001       \[--6.23, 6.23\]         .99          1.98        \[--6.72, 10.7\]         .65
   Nerve sparing bilateral                                                        −2.37        \[--7.36, 2.61\]         .35          −3.26       \[--10.70, 4.17\]        .39
   Early RT                                                                       −6.12        \[--29.7, 17.49\]        .61                                               
   Any RT                                                                         −0.13        \[--6.73, 6.44\]         .97          3.35        \[--6.84, 13.5\]         .52
  Bowel symptoms                                                                                                                                                          
   Age                                                                            −0.03        \[--0.17, 0.10\]         .63          −0.04       \[--0.18, 0.09\]         .52
   Pre-op bowel                                                                   0.10         \[--0.012, 0.21\]        .08          0.09        \[--0.02, 0.21\]         .09
   Non-specimen confined^[a](#table-fn7-1557988319854555){ref-type="table-fn"}^   **2.67**     **\[0.79, 4.54\]**       **.005**     **2.78**    **\[0.81, 4.6\]**        **.007**
   Early RT                                                                       0.27         \[--10.6, 11.2\]         .96          −1.90       \[--13.07, 9.26\]        .74
   Any RT                                                                         1.27         \[--1.76, 4.31\]         .41          −0.23       \[--3.55, 14.06\]        .89
  Treatment-related symptoms                                                                                                                                              
   Age                                                                            −0.09        \[--0.29, 0.11\]         .39          −0.14       \[--0.33, 0.05\]         .15
   Pre-op treatment related                                                       **0.36**     **\[0.25, 0.47\]**       **\<.001**   **0.33**    **\[0.22, 0.44\]**       **\<.001**
   Non-specimen confined^[a](#table-fn7-1557988319854555){ref-type="table-fn"}^   **6.05**     **\[3.23, 8.87\]**       **\<.001**   **5.09**    **\[2.3, 7.87\]**        **\<.001**
   Hormone therapy at 24 months                                                   **10.06**    **\[2.5, 17.61\]**       **.009**     3.44        \[--3.92, 10.79\]        .36
  Sexual activity                                                                                                                                                         
   Age                                                                            **−1.12**    **\[--1.62, --0.62\]**   **\<.001**   **−0.75**   \[--**1.25, --0.25\]**   **.003**
   Pre-op sexual activity                                                         **0.33**     **\[0.22, 0.44\]**       **\<.001**   **0.25**    **\[0.12, 0.37\]**       **\<.001**
   Pre-op IIEF-5                                                                  **0.60**     **\[0.29, 0.92\]**       **\<.001**   0.13        \[--0.20, 0.47\]         .43
   Non-specimen confined^[a](#table-fn7-1557988319854555){ref-type="table-fn"}^   −**10.39**   **\[--17.54, 3.24\]**    **.005**     −4.55       \[--11.64, 2.53\]        .21
   Nerve sparing unilateral                                                       **10.88**    **\[0.19, 21.56\]**      **.046**     3.20        \[--7.44, 13.84\]        .56
   Nerve sparing bilateral                                                        **17.43**    **\[8.87, 21.56\]**      **\<.001**   6.73        \[--2.2, 15.68\]         .14
   Hormone therapy at 24 months                                                   **−33.11**   **\[--51.8, −14.4\]**    **.001**     −17.56      \[--36.77, 1.64\]        .07
  Sexual functioning                                                                                                                                                      
   Age                                                                            **−1.44**    **\[--1.93, --0.95\]**   **\<.001**   **−1.11**   **\[--1.58, --0.65\]**   **\<.001**
   Pre-op sexual functioning                                                      **0.34**     **\[0.22, 0.46\]**       **\<.001**   **0.36**    **\[0.25, 0.48\]**       **\<.001**
   Pre op IIEF-5                                                                  **0.59**     **\[0.27, 0.89\]**       **\<.001**   0.06        \[--0.24, 0.37\]         .69
   Non-specimen confined^[a](#table-fn7-1557988319854555){ref-type="table-fn"}^   −6.81        \[--14.20, 0.58\]        .07          −2.31       \[--0.89, 4.32\]         .49
   Nerve sparing unilateral                                                       10.67        \[--0.85, 22.19\]        .069         3.83        \[--6.8, 14.45\]         .48
   Nerve sparing bilateral                                                        **17.74**    **\[8.17, 27.3\]**       **\<.001**   8.18        \[--0.78, 17.14\]        .07
   Hormone therapy at 24 months                                                   **−40.90**   **\[--73.33, --8.4\]**   **.01**      −29.50      \[--59.24, 0.24\]        .052

*Note*. Coeff = coefficient; IIEF = 5-item version of the International Index of Erectile Function; ICIQ = International Consultation on Incontinence Questionnaire; QoL = quality of life.

Non-specimen-confined disease ≥pT3b or pN1 or R1.

QoL According to EORTC QLQ C30 {#section10-1557988319854555}
------------------------------

When exploring baseline overall QoL, analyzed by the C30 questionnaire, the cohort presented a high level of overall QoL ([Figure 2](#fig2-1557988319854555){ref-type="fig"}). Physical, role functioning, and social scores all had a mean value \>90%. A reduction of emotional score in the preoperative setting was detected, with a mean value of 75%. In the specific categories of QoL, an increased rate of insomnia was also found, possibly reflecting this stressful phase.

![QoL after RALP (black line represents preoperative scores and purple represents 24 month scores). QoL = quality of life; RALP = robot-assisted laparoscopic prostatectomy.](10.1177_1557988319854555-fig2){#fig2-1557988319854555}

The first 3 months after surgery are characterized by a significant deterioration in QoL scores ([Figure 2](#fig2-1557988319854555){ref-type="fig"}); although physical and global QoL return to baseline values at 3 months, role functioning and social QoL require more time to adjust. Of note, insomnia, which is better, though not statistically significantly, at 1 month (22 vs. 18, *p* = .34), is significantly reduced at 3-month follow-up (22% vs. 14%, *p* = \<.001; [Figure 2](#fig2-1557988319854555){ref-type="fig"}). Similarly, appetite is significantly improved at 3 months (6% vs. 4%, *p* \< .001), and so are diarrhea symptoms (8% vs. 6%, *p* = .02). Fatigue and pain, significantly higher 1 month after surgery, returned to baseline at 3 months.

One year after surgery, global, physical, role functioning, emotional, and social QoL were all ameliorated compared to preoperative values (all *p* \< .01; [Figure 2](#fig2-1557988319854555){ref-type="fig"}). Similarly, fatigue, pain, insomnia, appetite, and diarrhea were all significantly improved (all *p* \< .03), and no global QoL score was worse than the preoperative status. Globally, these results were maintained at 2-year follow-up.

Discussion {#section11-1557988319854555}
==========

QoL is a complex outcome to explore and PCa diagnosis and therapy can significantly alter the perception of life and its quality for a man ([@bibr9-1557988319854555]). Across current therapies for localized PCa, radical surgery is currently a mainstay of treatment ([@bibr18-1557988319854555]), and in the past 10, years the advent of robotics has changed the face of prostatectomy in Europe. Promising studies reported favorable ([@bibr8-1557988319854555]) and, at times, surprisingly excellent ([@bibr10-1557988319854555]) functional outcomes after RALP and, together with company and social marketing, these have raised the expectations of PCa patients regarding surgery results ([@bibr22-1557988319854555]). Although the major impact of continence and sexual function on QoL after RALP is obvious, urologic surgeons may underestimate the impact of other items, such as gastrointestinal morbidity and anxiety, on the overall QoL of patients. While patients may perceive RALP to be the same procedure, no matter the underlying cancer, with increasing use of magnetic resonance imaging (MRI) and the improvement of prostate biopsy techniques, a trend in inverse stage migration of candidates for prostatectomy has been observed, with higher grade and higher risk patients growing in the past years ([@bibr2-1557988319854555]). This translates into a modification of surgical techniques, including the use of wider resection techniques, change in application of nerve-sparing techniques, and lymph node dissection, which can present nonnegligible morbidity ([@bibr13-1557988319854555]). The dissection of a bilateral nerve-sparing RALP with no pelvic node dissection for organ-confined Gleason 7 (3 + 4) PCa cannot be considered the same operation as a wide resection of cT3 Gleason 9 (4 + 5) PCa associated with pelvic node dissection, and this translates into a modification of postoperative QoL, as seen in the current study.

The literature on QoL alteration after RALP is scarce and most surgeons advise and consult their patients based mainly on their personal experience rather than on published reports. The current research reports a large prospective series of patients undergoing RALP in Belgium, reporting modifications in QoL, both overall and specific to PCa, and explores risk factors for degradation in such QoL.

Urinary incontinence represents a source of major stress for patients undergoing radical prostatectomy, with potential significant impact on QoL ([@bibr12-1557988319854555]). In the present study a significant degradation in ICIQ score 1 month after surgery was found, with gradual recuperation of urinary continence later, in line with current studies ([@bibr6-1557988319854555]; [@bibr17-1557988319854555]; [@bibr21-1557988319854555]; [@bibr24-1557988319854555]). The modification in ICIQ score was accompanied by a significant increase in urinary-related QoL, measured by urinary symptoms of EORTC PR25 and bother from incontinence aid in the same questionnaire. Of note, at 3 months after surgery the only significant risk factor identified was preoperative urinary symptom score, meaning that patients who were already bothered before surgery were at a higher risk of maintaining a higher score in the early and late postoperative control. These results could be considered quite inevitable, given the impact of all other urinary organs (bladder, urethra, pelvic musculature) except the prostate in the pathophysiology of lower urinary tract symptoms (LUTS). Of note, the urinary symptoms of EORTC PR25 analyze storage symptoms (pollakiuria, nycturia) and pain during urination, rather than voiding symptoms. As the preoperative details of obstructed voiding and the International Prostate Symptom Score (IPSS) score are unknown, the presented data do not allow determining whether radical prostatectomy could potentially alleviate LUTS in patients presenting with obstructive micturition. Regarding bother from urinary incontinence, no significant risk factor was identified.

When comparing QoL measurement across studies, one must bear in mind sociocultural differences across the examined cohort, which may play a significant role in subjective perceptions of symptoms, their interpretation, and QoL expectations after oncologic surgery. Nonetheless, these results are comparable to those of current literature: ([@bibr28-1557988319854555]) reported data in 343 patients undergoing laparoscopic radical prostatectomy in a single center. Urinary symptoms were 15.9% at baseline and increased to 41% at 1 month after surgery (16% and 31%, respectively, in the current study). It is interesting to note that in such study the authors did not find a significant difference in QoL outcomes based on surgical experience. Moreover, similarly to this Belgian experience, the authors reported a baseline global QoL score of 77.2 + 18 (73 ± 21 in the present study), which normalized before 1 year postoperatively and finally increased to a significant higher level. Baseline and follow-up urinary symptom scores were comparable ([@bibr28-1557988319854555]). [@bibr26-1557988319854555] compared QoL results across patients undergoing direct RALP and patients who initially were elected for active surveillance and then were shifted to RALP. The authors reported similar postoperative scores, concluding that delaying radical treatment in favor of an initial surveillance did not jeopardize QoL outcomes.

While analyzing sexual QoL, the first important factor to keep in mind is baseline values. Indeed, median IIEF-5 across the present entire cohort was 16; moreover, when examining sexual-related QoL, median value of sexual activity and interest was 50%, with interquartile ranges not passing two thirds of the cohort. These results were comparable to or better than those reported from other countries ([@bibr11-1557988319854555]; [@bibr27-1557988319854555]; [@bibr28-1557988319854555]), although age and cultural differences most likely explain observed differences. Whether the recent diagnosis of PCa (and its associated anxiety) had a role in reducing the sexual drive of patients cannot be evaluated with the available data. However, of interest, baseline values were much more significant in the determination of postoperative sexual activity and function than surgical approach and in particular nerve-sparing technique. Globally, from the current analyses, age was the single most important factor in predicting early and late postoperative sexual activity and functioning. No significant association of unilateral nerve sparing with any of our early or late sexual outcomes in terms of QoL was found: As such, patients should be informed that other than increasing the risk of a positive surgical margin ([@bibr15-1557988319854555]), a unilateral nerve sparing may have no effect of postoperative sexual QoL.

Examining the EORTC Q30 questionnaire implies difficult interpretation, given its detailed analysis of QoL domains, no matter the primary organ from which the cancer arises. In the present study however, there are multiple interesting points that emerge. First, all functional scales improve 1 year after surgery: some faster, beginning at 1--3 months, such as the emotional scale (probably reflecting the reduced anxiety after surgery), others more smoothly, such as the role-functioning and the social-functioning scales, given the physiologic time needed for men to regain confidence after RALP. Nonetheless, all scores are significantly improved (all *p* \< .01) at 12 months follow-up, apart from cognitive function, which shows no modification as a consequence of surgery. Another item that improved immediately after surgery was insomnia, confirming the positive impact of the reduction of anxiety after the surgical trauma. Furthermore, the present data demonstrate that patients exhibit significant increase of symptoms, including pain, constipation, and fatigue up to 1 month after surgery, and globally it is not until the 3-month control that patients report return to baseline or improvement of these general symptoms. This information can be of importance when counseling and reassuring for patients before surgery.

This study is not devoid of limitations. First, some parameters including body mass index, membranous urethral length, and comorbidities, which may all potentially play a role in postoperative continence, erectile function, and QoL, were unavailable and could not be incorporated in the multivariate regression models. Second, analyses are not corrected by socioeconomic status, which may also modify perception of QoL ([@bibr14-1557988319854555]). Third, it is impossible to assess the compliance of patients in pelvic floor muscle training, adding a potential confounding bias. Finally, the variability of surgeon volume and experience may have introduced bias; however, the three surgeons in the present cohort present similar experience in RALP and this could increase the applicability of these results to other realities.

We nonetheless acknowledge that this was a purely prospective trial, thus limiting recall biases. Moreover, this is a cohort composed of European men, with social and cultural differences from U.S. men, adding significant information to the current knowledge on QoL after RALP. Finally, the long follow-up (24 months) allows a vivid representation of functional and QoL results after RALP and of how these results continue to improve and stabilize long after surgery.

Conclusions {#section12-1557988319854555}
===========

In this prospective study, detailed QoL outcomes of men undergoing RALP are reported. After a net reduction immediately after surgery, the vast majority of scores returned to baseline or are improved by 1 year. Preoperative urinary bother was significantly associated with early and late urinary-related QoL, while age was the most significant predictor of sexual-related QoL after surgery.
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